These factors suggest that infant exposure might be minimal even if semaglutide is present in breast milk
In terms of clinical evidence, randomized clinical trials have shown that the GLP-1 receptor agonist exenatide may reduce alcohol consumption, particularly in individuals with co-occurring alcohol use disorder and obesity (Klausen et al., 2022)
doi: 10.1007/978-981-13-1286-1_8
IV Push: A faster, concentrated delivery directly into the vein, often used for higher doses when time is a factor
For pure weight-loss endpoints, retatrutide outperforms semaglutide by roughly 9 percentage points at peak dose: 24.2% versus ~15% mean body-weight loss at comparable durations [3][4]
BPC-157 influences angiogenesis and vascular repair, while TB-500 supports cell migration and tissue remodeling